Retroviral Gene Transfer in Autologous Bone Marrow Transplantation for Adult Acute Leukemia
- 10 July 1996
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (11) , 1323-1329
- https://doi.org/10.1089/hum.1996.7.11-1323
Abstract
To evaluate whether marrow contributes to relapse after autologous bone marrow transplantation (AuBMT) for acute leukemia, transplanted marrow was marked with the G1N retroviral vector (Genetic Therapy Inc.) containing the neomycin phosphotransferase gene (neo). Between April 1992 and August 1993,4 patients were transplanted for acute myeloid leukemia (AML) in second complete remission (CR) and 1 patient for acute lymphoid leukemia in first CR. An average of 12.4% (range 5–19%) of transplanted marrow mononuclear cells were exposed to G1N vector for 4 hr. In the vector-treated portion of the marrow, 4.9% of GM-CFU and 3.6% of erythroid burst-forming units (BFU-E) were resistant to G418 in vitro. In the 5 patients, the polymerase chain reaction (PCR) detected the neo sequence on only two occasions after AuBMT. Of 4 patients surviving 1 year after transplantation, only 1 had evidence of gene marked cells by PCR. Two AML patients have relapsed, one of whom had evidence of neo sequences in the bone marrow at day 100 but not at relapse 11 months after AuBMT. The second patient relapsed 18 months after AuBMT but never had PCR evidence of neo sequences before or after relapse. Our results indicate vector-transduced autologous bone marrow from heavily pretreated adults with acute leukemia mark with low efficiency, although vector sequences have been detected in bone marrow and peripheral blood up to 1 year after transplant. Of the 2 relapsed patients, no evidence of vector-marked leukemic blasts have been detected. Gene marking in heavily treated adult patients undergoing autologous bone marrow transplantation for acute leukemia was associated with gene transfer into committed progenitors of approximately 4%. In contrast to findings in children, long-term evidence of vector marked cells was infrequently seen (1 of 4 evaluable patients). Retroviral vector was not detected in the leukemic cells of 2 patients who relapsed 11 and 18 months after transplantation.Keywords
This publication has 26 references indexed in Scilit:
- Detection of specific sequences among DNA fragments separated by gel electrophoresisPublished by Elsevier ,2006
- Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patientsThe Lancet, 1993
- Infection of Human Cells with Murine Amphotropic Replication-Competent RetrovirusesHuman Gene Therapy, 1993
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Retroviral-Mediated Gene Transfer of Bone Marrow Cells During Autologous Bone Marrow Transplantation for Acute Leukemia. University of IndianaHuman Gene Therapy, 1992
- Autologous Bone Marrow Transplant for Children with AML in First Complete Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of RelapseHuman Gene Therapy, 1991
- Comparison of the Effects of Growth Factors on Retroviral Vector-Mediated Gene Transfer and the Proliferative Status of Human Hematopoietic Progenitor CellsHuman Gene Therapy, 1990
- Amphotropic Murine Leukemia Retrovirus Is Not an Acute Pathogen for PrimatesHuman Gene Therapy, 1990
- Developmental potential and dynamic behavior of hematopoietic stem cellsCell, 1986
- Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursorsNature, 1985